Expanding the Use of Presbyopia-Correcting IOLs in Patients with Comorbid Conditions

Eric D. Donnenfeld, MD

Ophthalmic Consultants of Long Island and Connecticut
Trustee, Dartmouth Medical School
Clinical Professor of Ophthalmology
New York University
New York, New York

Marjan Farid, MD

Director of Cornea, Cataract, and Refractive Surgery
Vice Chair of Ophthalmic Faculty
Clinical Professor of Ophthalmology
Gavin Herbert Eye Institute
University of California, Irvine

Constance Okeke, MD, MSCE

Glaucoma & Cataract Specialist
CVP Physicians/Virginia Eye Consultants
Assistant Professor of Ophthalmology
Eastern Virginia Medical School
Norfolk, Virginia

 

Karl G. Stonecipher, MD

Clinical Associate Professor of Ophthalmology
University of North Carolina, Chapel Hill
Associate, Piedmont Eye Surgical and Laser Center
Greensboro, North Carolina
Director, TLC Laser Eye Centers
Greensboro and Raleigh, North Carolina

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Eric D. Donnenfeld, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allegro, Allergan , Alcon Vision, Avellino Labs, Bausch + Lomb, Carl Zeiss Meditec, CorneaGen, Covalent, BVI, Blephex, Dompé, ELT Sight, EyePoint Pharma, Foresight, Glaukos, Ivantis, Johnson & Johnson Vision, Kala Pharmaceuticals, Katena, Lacripen, LensGen, Mati Therapeutics, MDBackline, Merck, Mimetogen, Nanowafer, Novabay, Novartis, Novaliq, Ocular Innovations, Oculis, Odyssey, Omega Ophthalmics, Oyster Point Pharma, Pfizer, Pogotec, Ocuhub, Omeros, PRN, RegenerEyes, ReTear, RPS, Shire, Strathspey Crown, Sun Pharma, Surface, Tarsus, Tearlab, Tearscience, Thea, TLC Laser Centers, Veracity, Versant Ventures, Visionary Venture, and Visus Therapeutics.  Stock/Shareholder: Avedro, CorneaGen, Covalent, ELT Sight, EyePoint Pharma Glaukos, Ivantis, Lacripen, LensGen, Mati Therapeutics, MDBackline, Mimetogen, Novabay, Ocuhub, Ocular Innovations Oculis, Orasis Pogotec, RegenerEyes, ReTear, RPS , Strathspey Crown, Surface, Tarsus, Tearlab, Veracity, Versant Ventures, Visionary Ventures, and Visus Therapeutics.

Marjan Farid, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, BioTissue, Carl Zeiss Meditec, CorneaGen, Dompé, Eyepoint Pharmaceuticals, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, and Novartis.

Constance Okeke, MD, MSCE,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Akorn, Alcon Vision, Allergan, Bausch + Lomb, Nova Eye Medical, Eyenovia, Glaukos, Ivantis, MST, Sight Sciences, Sun Pharmaceutical Industries, and Thea.  Grant/ResearchSupport: Bausch + Lomb, Glaukos, and Nicox. Speaker’s Bureau: Aerie Pharmaceuticals, Allergan, Bausch + Lomb, MST, and Sun Pharmaceutical Industries. Stock/Shareholder: Mediprint, and Visionology. Other Financial Support: Kugler Publications. 

Karl G. Stonecipher, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Grant/ResearchSupportand Speaker’s Bureau: Acufocus, Alcon Vision, Allergan, Alphaeon, Bausch + Lomb, Espansione, Johnson & Johnson Vision, Greenlight, Kala, Marco, Nidek, Novartis,  Presbia, and Refocu. Stock/Shareholder: Alphaeon, Pogotec, and Strathspey Crown. 

EDITORIAL SUPPORT DISCLOSURES
The staff and planners from Evolve and The Fundingsland Group have no financial relationships with commercial interests. 

Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.